Filling the need for trusted information on national health issues…

Drug Initiative Granted Rights To Develop TB Compounds For Potential Treatment Of NTDs

The Drugs for Neglected Diseases Initiative (DNDi) now has the rights to “develop a class of potential anti-[tuberculosis] compounds” for the treatment of Chagas disease, African sleeping sickness and leishmaniasis, Reuters reports (Nebehay, 7/7). The deal, approved by the Global Alliance for TB Drug Development and backed by the Bill & Melinda Gates Foundation, is the “first-ever royalty-free license agreement between two not-for profit drug developers,” according to a TB Alliance press release (7/7).

“There are innovative ways to share knowledge, to avoid duplication in research, thereby saving costs and speeding up the R & D process for the benefit of the patients,” DNDi’s Executive Director Bernard Pecoul said, according to Reuters. “One of the furthest advanced and most promising TB drug candidates covered by the agreement” is a compound from the nitroimidazole drug class, which “many pathogens causing neglected diseases are susceptible to,” according to drug developers (7/7).

The Henry J. Kaiser Family Foundation Headquarters: 2400 Sand Hill Road, Menlo Park, CA 94025 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/KaiserFamFound

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in Menlo Park, California.